ROBERT SHALWITZ, M.D.
Medical Practice at Bryden Rd, Columbus, OH

2006003, Feb 16, 2006

Apr 28, 2005

11/117236

Keith Rushlow - Pickerington OH, US
Robert Shalwitz - Bexley OH, US
Terrence Mazer - Reynoldsburg OH, US
Normanella Dewille - Columbus OH, US
Tapas Das - Worthington OH, US
Anand Seth - Dublin OH, US

A61K 36/30, A61K 36/064, A61K 31/202, A61K 31/198, A61K 33/04

424667000, 424702000, 514561000, 424195160, 424776000, 514560000

Disclosed are compositions and corresponding methods for treating fibrocystic breast disease or other breast-related disease or condition. The compositions comprise, per serving or dose, from zero to about 400 μg selenium, from about 100 mg to about 6000 mg gamma linolenic acid, and about 0.15 mg to about 5 mg iodine, with nutritional embodiments further comprising one or more of protein, fat, carbohydrate, vitamins, and minerals and providing from about 50 to about 1000 kcal of energy per severing or dose. Also disclosed are in-vitro studies showing that certain combinations of gamma linolenic acid, iodine, and/or selenium may 1) inhibit breast cancer or fibrocystic cell proliferation, 2) reinforce the function of tight junctions of endothelial cells and of mammary epithelial cells in estrogen-sensitive conditions, and 3) reduce the risk of vascular invasion by breast cancer cells.

2006010, May 18, 2006

Dec 27, 2005

11/318677

Robert Shalwitz - Bexley OH, US
Tapas Das - Worthington OH, US
Paul Johns - Columbus OH, US
James Leach - Columbus OH, US

A61K 31/7076, A61K 31/7072

514047000, 514049000

Disclosed are compositions and methods for alleviating mucositis, wherein said methods and compositions are directed to the formulation or use of selected nucleoside derivatives, especially ADP-ribose, that conform to the general formula A-B-X and pharmaceutically acceptable salts thereof, wherein “A” is a nucleoside structure selected from adenosine, guanosine, and uridine; “B” is a diphosphate linkage attached to the 5′ carbon of the nucleoside ribose moiety; and “X” is attached to B an is a moiety selected from hydrogen, furanose, or pyranose. Also disclosed are pharmaceuticals and nutritional liquid embodiments thereof, including lozenges, mouthwashes, or other product forms that effectively coat the oral, laryngeal or other mucosal areas. It has been found that these compositions and methods effectively alleviate mucositis in susceptible individuals, especially when administered prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof.

2006021, Sep 21, 2006

Dec 5, 2005

11/293513

George Bobotas - Tarpon Springs FL, US
Robert Shalwitz - Bexley OH, US
Roelof Rongen - Califon NJ, US

A61K 31/426, A61K 31/22, A61K 31/202, A61K 31/192

514369000, 514571000, 514560000, 514547000

A method and composition for blood lipid therapy that comprises administering to the subject an effective amount of a PPAR agonist and/or antagonist and an omega-3 fatty acid. The methods and compositions include combination products or concomitant therapy for the treatment of subjects with hypertriglyceridemia, hypercholesteremia, mixed dyslipidemia, vascular disease, artherosclerotic disease and related conditions, obesity, the prevention or reduction of cardiovascular and vascular events, the reduction of insulin resistance, fasting glucose levels and postprandial glucose levels, and/or the reduction of incidence and/or the delay of onset of diabetes.

2010001, Jan 14, 2010

Sep 17, 2009

12/561558

Roelof M.L. RONGEN - Califon NJ, US
Robert A. SHALWITZ - Bexley OH, US
Douglas KLING - Parsippany NJ, US

A61K 31/505, A61K 31/47, A61K 31/404, A61K 31/40, A61K 31/366, A61K 31/202

514275, 514311, 514419, 514423, 514460, 514560

Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.

2013015, Jun 20, 2013

Feb 19, 2013

13/770135

Robert Shalwitz - Bexley OH, US
Joseph H. Gardner - Cincinnati OH, US

Aerpio Therapeutics Inc. - Cincinnati OH

A61K 31/4412, A61K 31/4545, A61K 31/541, A61K 31/501, A61K 31/4439, A61K 31/5377, A61K 31/55, A61K 31/496

51421208, 514348, 51421704, 514318, 51425202, 51425312, 514343, 514341, 514278, 5142355, 5142278

Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1-alpha (HIF-1α) and diseases, conditions, or syndromes related thereto, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are pharmaceutical compositions comprising HIF-1α prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF-1α.

2013009, Apr 18, 2013

Oct 15, 2012

13/652154

Robert Shalwitz - Bexley OH, US

AERPIO THERAPEUTICS, INC. - Cincinnati OH

A61K 39/395, A61K 38/02, A61K 31/7088, A61P 27/02

4241351, 4241581, 514 208, 4241461, 4241781

Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.

2009018, Jul 16, 2009

Jan 5, 2007

12/087411

Roelof M. L. Rongen - Califon NJ, US
Robert A. Shalwitz - Bexley OH, US
Ihor Terleckyj - Bloomfield NJ, US

A61K 31/20, A61K 31/426, A61P 1/16

514365, 514560

Methods and compositions comprising peroxisomal and/or mitochondrial beta oxidation stimulating agents to reverse or resolve, slow the progression of, treat or prevent the development of fatty liver and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure. An active agent that by itself is associated with an increased risk of fatty liver development and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure, may be administered in combination with peroxisomal and/or mitochondrial beta oxidation stimulating agents. A combination regimen involving such agents, as simultaneous or concomitant therapy, or as a fixed dosage form, is also provided.

2013009, Apr 18, 2013

Oct 15, 2012

13/652203

Robert Shalwitz - Bexley OH, US

AERPIO THERAPEUTICS, INC. - Cincinnati OH

A61K 39/395, A61P 29/00, A61P 35/00, A61P 31/00, G01N 33/566, A61P 31/04, A61P 31/12, A61P 31/10, A61P 35/04, A61P 9/14, A61P 11/00

424 852, 4241461, 4241331, 4241781, 436501

Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.

2008008, Apr 10, 2008

Sep 7, 2007

11/851867

Roelof M.L. Rongen - Califon NJ, US
Robert A. Shalwitz - Bexley OH, US
Douglas Kling - Parsippany NJ, US
Ralph T. Doyle - Milford NJ, US

Reliant Pharmaceuticals, Inc. - Liberty Corner NJ

A61K 31/20, A61K 31/225, A61K 31/35, A61K 31/40, A61K 31/405, A61K 31/47, A61K 31/505, A61P 3/00

514275, 514311, 514415, 514423, 514460, 514548, 514560

Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.